This is particularly important because predicted beneficial effects of targeting a protein may be countered by on-target side effects on other traits, as we saw where the autoimmune-protective variant in PTPN22 was associated with an increased risk of skin cancer. This evidence concerns the gene PTPN22 and skin neoplasm.